Duran, I., Duran, M. A. C., Carbonero, I. G., Villares, A., Sánchez-Escribano, R., Calleja, J., Sagastibelza, N., Villafruela, A., Galante, I., Dominguez, J. L., Pous, A. F., Servian, P., Lainez, N., Grasa, V., Anido, U., Cimadevila, A., Dominguez, M., Muro, X. G. D., Buisan, O., Puente, J. (2025). Phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patients with muscle invasive bladder cancer ineligible or who refuse cisplatin-based chemotherapy: The PRISMA-1 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps884